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for Ovulation Induction in 
Infertile Women with Ovulatory 
Dysfunction (PCO)
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Abstract
A RCT conducted to assess the efficacy of letrozole as an ovulation induction 
agent in infertile women, and to compare the effectiveness of letrozole with the 
current standard agent, clomiphene citrate given for three successive cycles on  
the induction of ovulation. Forty-five infertile women with anovulation included, 
the subjects were randomly divided into two groups; subjects were allocated to 
either CC (100) or letrozole (5 mg) daily—5 days starting on the third day of 
menses, for 3 months. On stimulation day 12 subjects, serum estradiol and trans-
vaginal sonography to document the number of follicles was done. On stimula-
tion day 21 subjects, serum progesterone and ultrasound for the thickness of 
endometrium was done. Participants were followed-up monthly. Results revealed 
that the mean number of follicles reaching >18 mm and endometrial thickness in 
the letrozole comparable to those receiving clomiphene citrate. Letrozole showed 
lower estradiol level compared to Clomiphene citrate (P < 0.05). Ovulation 
occurred in 84.4%, 78.1% in the letrozole and clomiphene citrate, respectively, and 
pregnancy rate is 18.8% in the letrozole group compared to 15% in the clomiphene 
citrate group. In conclusion, there was no significant increase in the number of 
follicles, endometrial thickness and pregnancy rate induced by letrozole compared 
with clomiphene citrate.
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1. Introduction
Many controversies surround the treatment of infertile women with polycystic 
ovary syndrome (PCOS). Before any intervention is initiated, pre-conceptional coun-
selling should be provided emphasizing the importance of lifestyle, especially weight 
reduction and exercise in overweight women, smoking, and alcohol consumption [1].
The recommended first-line treatment for ovulation induction remains the anti-
estrogen clomiphene citrate (CC). Recommended second-line intervention, should 
CC fail to result in pregnancy, is either exogenous gonadotropins or laparoscopic 
ovarian surgery (LOS). The use of exogenous gonadotropins is associated with 
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increased chances for multiple pregnancies, and, therefore, intense monitoring of 
ovarian response is required. Laparoscopic ovarian surgery alone is usually effec-
tive in less than 50% of women, and additional ovulation induction medication is 
required under those circumstances. Recommended third-line treatment is in vitro 
fertilization (IVF) [1].
Aromatase inhibitors aromatase inhibitors act not only by decreasing circulating 
levels of estrogen, but also by directly blocking local estrogen production in the 
breast tumor.
In premenopausal women, it causes an increase in gonadotropin secretion 
because of the reduced negative feedback of estrogen to the pituitary.
It also leads to ovarian stimulation, an increase in ovarian size, which may result 
in ovarian cysts in premenopausal females [2].
Kafy and Tulandi [3] found that letrozole in a dose of 5 mg daily for 5 days is 
associated with a thicker endometrium and a better pregnancy rate. It is as effective 
as gonadotropin but yet less expensive. Moreover, induction of ovulation with FSH 
injections is carried with relative risks of multiple gestations and severe ovarian 
hyperstimulation syndrome [4]. The benefit of the use of aromatase inhibitors has 
not yet been proven in large studies [5].
Gregoriou et al. [6] stated that ovarian stimulation with letrozole is associated 
with acceptable pregnancy rates compared with gonadotropin with significant 
less cost, risks, and patient inconvenience. In addition, suggests that clomiphene 
suppresses endometrial receptivity more than letrozole, and they concluded that 
letrozole might be an appropriate drug for ovulation induction. Fortunately, 
Badawy et al. [7] documented safety of letrozole and clomiphene citrate for both 
the mother and fetuses.
Yet, the benefit of the use of aromatase inhibitors has not yet been proven in 
large studies, and further randomized-controlled studies are warranted to define 
more clearly the efficacy and safety of letrozole in human reproduction.
2. Material and methods
Condition phase: Infertility due to anovulation.
Intervention: Patients were assigned to the letrozole or clomiphene citrate. 
Patients were enrolled and followed-up. The Ethics Committee of the King 
Abdulaziz University Hospital approved this study. Written informed consent was 
obtained from each patient.
Study design: Treatment, randomized, double-blind, efficacy study comparing 
letrozole versus clomifene citrate for ovulation induction.
Setting: A university teaching hospital.
Primary outcome measures: Ovulation rate, number of growing and mature 
follicles during treatment, serum estradiol level, serum progesterone level, endome-
trial thickness.
Secondary outcome measures: Hyperstimulation, miscarriage rate, multiple 
pregnancy rate, and ectopic pregnancy trial population: 44 infertile females were 
assigned to the study according to certain inclusion criteria.
Inclusion criteria
1. Age: 25–40, BMI < 30.
2. Infertility due to anovulation.
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3. No recent (within 3 months) treatment for induction of ovulation.
4. Normal semen analysis.
5. Proven patency of at least one fallopian tube.
6. Had no other pelvic pathology.
Exclusion criteria
1. Inability to give informed consent
2. Hypersensivity to letrozole or clomiphene citrate
3. Excess prolactin levels
4. Other causes of infertility
5. Absence of any inclusion criteria.
This double-blind randomized-controlled trial was conducted in 44 infertile 
patients attending the Department of Obstetrics and Gynecology, King Abdulaziz 
University Hospital, Jeddah over a period of 1 year. Forty-four infertile women, 
aged between 25 and 40 years with infertility for 2 years or more, of unprotected 
coitus without conception in patients who have never conceived before, because 
of anovulation related to PCOS, were recruited for study after obtaining informed 
consents from the couples. PCOS diagnosis required the presence of two of three 
criteria, i.e., oligomenorrhea and/or anovulation, clinical and biochemical signs 
of hyperandrogenism, and/or polycystic ovaries on ultrasound. Couples with any 
other significant subfertility factor in either of the partner detected by pre-recruit-
ment investigations were not included in this study. The Ethics Committee of the 
King Abdulaziz University Hospital approved this study.
All patients were screened for the hormonal profile, including the follicle-stim-
ulating hormone, luteinizing hormone, prolactin, thyroid-stimulating hormone, 
estradiol, a pelvic ultrasound for confirmation of polycystic changes in the ovary, 
hysterosalpingography to determine tubal patency, Semen analysis in the patient’s 
partner to rule out malefactor.
Computer-assisted randomization was done and concealment was ensured. The 
candidates were randomly divided into two groups. Patients were allocated to either 
group (I), where patients received 5 mg of letrozole once daily (Femara®, Novartis, 
Basel, Switzerland), or group (II), where patients received 100 mg of CC once 
daily (Clomid®, Sanofi Aventis, France), for 5 days starting on day 3 of menses, for 
the first, second, and third month. Follow-up of ovulation and endometrial thick-
ness was monitored by transvaginal ultrasonographic folliculometry by the same 
operator by the same observer. Timed intercourse was advised 24 h after measuring 
dominant follicle of >18 mm till 12 h post ovulation.
Subjects returned to the clinic on stimulation day 12 for blood sampling to 
analyze estradiol and were undergone transvaginal sonography to document on the 
number of follicles (Note: Stimulation day 1 equals the first day of study drug).
Blood sampling was repeated on stimulation day 21 for the analysis of serum 
progesterone. Ovulation was confirmed by a progesterone level 10 ng/mL. If the 
results of the progesterone test indicate that the patient has not ovulated, the sub-
ject was brought back 1–2 days later for a repeat progesterone test. Also, ultrasound 
for assessment of the thickness of the endometrium was done.
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In ovulatory cycles, a pregnancy test was performed 3 days post missed period. 
Subjects with a positive pregnancy test were supplemented with micronized proges-
terone vaginally. Participants were evaluated for three courses of intervention.
Subjects may be allowed to continue for up to two additional treatment cycles if 
they failed to achieve clinical pregnancy in their first treatment cycle, and did not 
experience other mandatory withdrawal condition. A follow-up visit was arranged 
for each group every month at the second day of menstruation until 3 months after 
recruitment or at any time during the trial if the pregnancy was achieved.
2.1 Statistical analysis
The data were analyzed with the Statistical Program SPSS version 16. 
Descriptive statistics comprised the mean and standard deviation (SD), analytical 
statistics comprised the t-test to make comparisons between independent quantita-
tive means, and the Anova test to make comparisons between the different groups. 
P value < 0.05 was significant. Pearson correlation was done between different 
parameters.
3. Results
Results obtained during the term of the project and data analysis. Patients were 
randomized so as, 24 women of mean age (30.2 ± 4.3) years received letrozole; 
whereas, 20 women of mean age (29.8 ± 4.7) years received clomiphene citrate. 
Group (I) had a body mass index of (28.2 ± 2.1); whereas, group (II) had a body 
mass index of (27.4 ± 2.2). There was no significant difference between the groups 
as regard age or body mass index (P > 0.05) (Table 1) and the baseline hormonal 
profiles of the two groups (Table 2).
There was no significant statistical difference between letrozole group and the 
clomiphene citrate group concerning the following hormones: serum FSH day 2 
(5.5 ± 1.9 versus 5.9 ± 1.5 IU/ml), serum LH day 2 (4.1 ± 2.4 versus 4.4 ± 2.3 mIU/ml), 
and serum E2 day 2 (53.1 ± 11.4 versus 50.9 ± 15 pmol/L).
FSH LH TSH Prolactin Estradiol
IU/ml mlU/ml ulU/m mlU/L pmol/L
Letrozole (n = 24) 5.5 ± 1.9 4.1 ± 2.4 1.9 ± 0.1 12.2 ± 2.6 53.1 ± 11.4
Clomiphene citrate (n = 20) 5.9 ± 1.5 4.4 ± 2.3 2.0 ± 0.2 13.4 ± 1.6 50.9 ± 15
Significance NS NS NS NS NS
Significant change: P < 0.05.
Table 2. 
Baseline hormonal parameters of the study groups.
Age BMI
Letrozole (n = 24) 30.2 ± 4.3 28.2 ± 2.1
Clomiphene citrate (n = 20) 29.8 ± 4.7 27.4 ± 2.2
Significance NS NS
Significant change: P < 0.05.
Table 1. 
Baseline parameters of the study groups.
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The primary outcome measures were a number of mature follicles and endome-
trial thickness (in mm); secondary outcome measures were the pregnancy rate and 
miscarriage rate. The number of follicles showed no statistically significant (P > 0.05) 
difference between the groups (5.8 ± 3.6 for Group I versus 3.2 ± 3.3 in Group II) in 
cycle I. Endometrial thickness showed no statistically significant (P > 0.05) differ-
ence (9.07 ± 0.3 for Group I versus 4.08 ± 0.3 cm for Group II) (Table 3).
The mean number of follicles reaching >18 mm was significantly higher in 
patients who received letrozole (4.5 ± 4.5) than in those receiving clomiphene 
citrate (3.6 ± 3.6), although this difference was found non-significant. Letrozole 
and clomiphene citrate showing no significant difference (P > 0.05) as regards the 
endometrial thickness (1.1 ± 0.2 versus 1.2 ± 0.2) (Table 3). There is an insignifi-
cant difference between clomiphene citrate and letrozole as regard endometrial 
thickness and number of follicles through the 3 cycles. Clomiphene citrate signifi-
cantly increased estradiol and progesterone levels compared to letrozole in cycle 1 
and cycle 3 (Tables 3–5).
Estradiol Progesterone Follicles Endometrium Pregnancy
pmol/L mol/L Number Thickness (cm) Rate
Letrozole (n = 24) 4.5 ± 455.7* 47.6 ± 34.4 4.5 ± 4.5 1.1.2 ± 0.2 2.0
CC (n = 20) 2.5 ± 2127.6 62.2 ± 62.8 3.6 ± 3.6 1.2 ± 0.2 1.9 ± 0.2
Significance 0.001 0.017 0.820 0.724 0.030
CC = clomiphene citrate.
Significant change: P < 0.05.
Table 3. 
Effect of letrozole versus clomiphene citrate on estradiol, progesterone, no. of follicles and endometrial thickness 
in cycle 1.
Estradiol Progesterone Follicles Endometrium Pregnancy
pmol/L mol/L Number Thickness (cm) Rate
Letrozole (n = 24) 4.2 ± 656.7* 39.6 ± 31.1 5.8 ± 3.6* 1.07 ± 0.3 1.8 ± 0.3
CC (n = 20) 1.5 ± 904.5 48.9 ± 57.1 3.2 ± 3.3 1.08 ± .3 2.0 ± 0.2
Significance 0.25 0.14 0.46 0.81 0.02
CC = clomiphene citrate. 
Significant change: P < 0.05.
Table 4. 
Effect of letrozole versus clomiphene citrate on estradiol, progesterone, no. of follicles and endometrial thickness 
in cycle 2.
Estradiol Progesterone Follicles Endometrium Pregnancy
pmol/L mol/L Number Thickness (cm) Rate
Letrozole (n = 24) 3.9 ± 349.09 36.8 ± 26 5.1 ± 4.8 1.05 ± 0.2 2.0 ± 0.3
CC (n = 20) 4.08 ± 5443.4 51.3 ± 68.5 1.3 ± 1.5 1.09 ± 0.4 2.0 ± 0.2
Significance 0.007 0.05 0.26 0.10 NS
CC = clomiphene citrate. 
Significant change: P < 0.05.
Table 5. 
Effect of Letrozole versus clomiphene citrate on estradiol, progesterone, no. of follicles and endometrial 
thickness in cycle 3.
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A comparison of the number of pregnancies achieved in the groups showed 
insignificant statistical difference (P < 0.05). No multiple pregnancies occurred in 
both groups (Table 6).
Anova between the 3 cycles revealed that there is no significant difference 
between estradiol, progesterone levels, number of follicles, and endometrial thick-
ness. Post Hoc Tests also revealed insignificant differences between the outcomes in 
the 3 cycles.
4. Discussion
Detailed scientific discussions of the results obtained during the term of the 
project, and related past results obtained in the field of this research area. Although 
clomiphene citrate is considered the first-line drug for ovulation induction in 
women with PCOS, a significant proportion of women do not respond to this 
treatment [8]. Letrozole, a third-generation aromatase inhibitor, is suggested for 
ovulation induction [9].
Letrozole initiates ovulation by decreasing the conversion of androstenedione 
and testosterone to estrogen in the ovary. The inhibition of estrogen production, 
in turn, increases GnRH release and pituitary follicle-stimulating hormone (FSH) 
synthesis [10]. Clomiphene citrate acts by blocking the negative feedback of endog-
enous estrogen at the level of the hypothalamus and pituitary gland and promoting 
an increase in the pulsatile release of luteinizing hormone and follicle-stimulating 
hormone. However, clomiphene citrate has an antagonistic effect on the endome-
trium and may reduce endometrial thickness [11].
The results of this prospective randomized study showed that letrozole was 
as effective as clomiphene citrate for induction of ovulation with an insignificant 
change in the number of mature follicles and endometrial thickness. Atay et al. [8] 
reported that letrozole and clomiphene citrate were effective for ovulation induc-
tion in PCOS, but in contrast to the present study, they found greater endometrial 
thickness in the letrozole group.
In the present study, clomiphene citrate significantly increased estradiol and 
progesterone levels compared to letrozole in cycle one and cycle 3. Badawy et al. [7] 
found that levels of serum estradiol and progesterone were statistically significantly 
higher in the clomiphene citrate group compared to letrozole.
The hormonal changes could be explained by clomiphene citrate (CC) binds to 
estrogen receptors (ERs) for an extended period of time due to its structural simi-
larity to estrogen. This will deplete ER concentrations. The antiestrogenic effect on 
the hypothalamus and the pituitary is believed to be the main mechanism of action 
for ovarian stimulation. Depletion of hypothalamic ERs prevents correct interpreta-
tion of circulating estrogen levels; estrogen concentrations are falsely perceived 
as low leading to reduced estrogen-negative feedback on GnRH production and 
No. of pregnancy Miscarriage
Letrozole (n = 24) 4 0
Clomiphene citrate (n = 20) 3 0
Significance 0.49 NS
Significant change: P < 0.05.
Table 6. 
Effect of letrozole versus clomiphene citrate on number of pregnancies pregnancy and miscarriages in the 
3 cycles.
7Effect of Aromatase Inhibitors versus Clomiphene Citrate for Ovulation Induction in Infertile…
DOI: http://dx.doi.org/10.5772/intechopen.90270
Author details
Hassan S.O. Abduljabbar1*, Magda Hagras1,2 and Rania Magadmy3
1 Faculty of Medicine, King Abdulaziz University, Kingdom of Saudi Arabia
2 Faculty of Medicine, Suez Canal University, Egypt
3 Clinical Trial Unit, King Fahd Medical Research Centre, King Abdulaziz 
University, Kingdom of Saudi Arabia
*Address all correspondence to: profaj17@yahoo.com
subsequent increased gonadotropin (FSH and LH) secretion. The rise of FSH pro-
motes growth of ovarian follicles and ovulation in anovulatory women. It is believed 
that the hypothalamus is the main site of action because in normally ovulatory 
women, CC treatment was found to increase GnRH pulse frequency [12].
Letrozole block estrogen-negative feedback, without depletion of ERs as 
occurs with CC. Inhibition of aromatization will block estrogen production from 
all sources and release the hypothalamic/pituitary axis from estrogenic negative 
feedback. The resultant increase in gonadotropin secretion will stimulate growth of 
ovarian follicles [13].
5. Conclusions and recommendations
Letrozole in patients with PCOS is as effective as clomiphene citrate in inducing 
ovulation; letrozole had a comparable effect to clomiphene citrate on endometrial 
thickness and number of follicles.
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